JPRN-UMIN000011337Completed未知
Study of visual and anatomical outcomes of aflibercept in good visual acuity baseline of wet age-related macular degeneration - Study of aflibercept in patients with wAMD
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Jichi Medical University
- Enrollment
- 39
Study Overview
Brief Summary
Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study. Shinichi Sakamoto, Hidenori Takahashi, Yuji Inoue, Yusuke Arai, Satoru Inoda, Natsuko Kakinuma, Yujiro Fujino, Tatsuro Tanabe, Hidetoshi Kawashima, Yasuo Yanagi Clinical ophthalmology (Auckland, N.Z.) 12 1137-1147 2018
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with anti-VEGF drug, photodynamic therapy 4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5) Active intraocular inflammation 6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7) Patient who the doctor in charge judges are ineligible for the study
Investigators
Similar Trials
Completed
Not Applicable
Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneratioAge-related macular degenerationJPRN-UMIN000016598Department of Ophthalmology, Jichi Medical University39
Completed
Phase 4
Intravitreal Aflibercept for Submacular HemorrhageExudative Age-related Macular DegenerationNCT03169660Kim's Eye Hospital29
Completed
Phase 4
Effect Aflibercept on Ocular PerfusionAnti Vascular Endothelial Growth FactorMacular DegenerationNCT03804099Augenabteilung Allgemeines Krankenhaus Linz20
Recruiting
Not Applicable
Aflibercept in Recurrent or Persistent CNVAge Related Macular DegenerationIntravitreal InjectionsDiabetic Macular EdemaNCT02669953Medical University of Vienna80
Completed
Phase 4
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3Macular EdemaNCT03355638Università degli Studi di Brescia60